The selling is minimal relative to market cap ($23.2B) and appears tied to option exercises and tax obligations, not negative sentiment. Traders should monitor for follow-up filings or commentary around earnings or pipeline updates, but no immediate signal from this cluster.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 17 $540.02entry
- T+1 · 8mo ago −1.79%α −0.40% · $530.35
- T+5 · 8mo ago −1.52%α +1.11% · $531.82
- T+20 · 7mo ago +6.96%α +2.61% · $577.58
- T+60 · 5mo ago +1.00%α −8.99% · $545.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple United Therapeutics insiders, including CEO Martine Rothblatt and CFO James Edgemond, engaged in significant stock transactions over the past week, primarily involving derivative exercises and tax-related share withholdings. The open-market sales totaled $684,416, while non-cash transactions (exercises and tax withholdings) amounted to over $10.1 million in value. This cluster reflects routine equity settlement activity rather than strategic selling.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 1,009 shares for $537,803 across three open-market transactions; also exercised derivatives on 61,499 shares at $146.03 strike price
- CFO James Edgemond had $2.51M in tax withholding (F transaction) and exercised derivatives on 10,380 shares (non-cash)
- COO Michael Benkowitz had $4.20M in tax withholding (F transaction)
- EVP Paul Mahon sold 753 shares for $397,184 and exercised derivatives on 17,195 shares
- Director Judy Olian sold 200 shares for $107,088; Director Jan Malcolm sold 45 shares for $24,008
- Total open-market sales: $684,416 across 4 insiders
- Total non-cash transactions (M, F, A): over $10.1 million in value
- All transactions occurred between March 15–19, 2026
Financial Impact
$684,416 in net open-market selling; $10.1M in non-cash derivative settlements and tax withholdings
Risk Factors
- Perception risk from high-dollar tax withholdings, though common in biotech executives with large option grants
- Concentration of transactions around CEO and CFO could draw scrutiny if pattern continues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-UTHR-1773952260021 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers